Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - ENDO HEALTH SOLUTIONS INC. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 13, 2011 (January 7, 2011)
Endo Pharmaceuticals Holdings Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-15989 | 13-4022871 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 100 Endo Boulevard, Chadds Ford, PA | 19317 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code (610) 558-9800
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On January 7, 2011, Endo Pharmaceuticals Holdings Inc. (“Endo” or the “Company”) received a complete response letter from the U.S. Food and Drug Administration (“FDA”) regarding the New Drug Application (“NDA”) for its new formulation of OPANA® ER designed to be crush resistant.
On January 7, 2011, the Company announced the receipt of this complete response letter, and a copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit Number |
Description | |
| 99.1 | Endo Pharmaceuticals Holdings Inc. Press Release dated January 7, 2011 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| ENDO PHARMACEUTICALS HOLDINGS INC. | ||
| (Registrant) | ||
| By: |
/S/ CAROLINE B. MANOGUE | |
| Name: |
Caroline B. Manogue | |
| Title: |
Executive Vice President, Chief Legal Officer & Secretary | |
Dated: January 13, 2011
INDEX TO EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Endo Pharmaceuticals Holdings Inc. Press Release dated January 7, 2011 | |